NOVOCURE LIMITED
NVCR · NASDAQ
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Novocure's commercialized products are approved for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer.
ESG Scores
Overall ESG6.6
Environmental7.7
Social4.5
Governance6.8
Gender Diversity
Female Directors0.22219999999999998%
Female Executives0.12903225806451613%
CEO GenderMale
Market Data
Price$12.67-0.16 (-1.25%)
Market Cap$1.44B
P/E Ratio—
EPS$—
52W High$20.06
52W Low$9.82
Beta0.76